Novelix Pharmaceuticals Limite

BSE: NOVELIX · Healthcare Research, Analytics & Technology · sector

₹59.20BSE close 2026-10-26

Key numbers

Market cap₹141 cr

Price₹59.20

52w high / low₹92 / ₹45

P/E31.7xSector median 27.9x

P/B3.0xSector median 3.0x

Book value₹19.5

Dividend yield–Sector median 0.34%

ROE11.3%Sector median 6.1%

ROCE8.8%Sector median 9.8%

OPM3.1%Sector median 8.4%

Debt / equity0.09xSector median 0.01x

EV/EBITDA31.1xSector median 14.8x

Interest cover38.7x

Current ratio2.14x

Sales growth 3y+411.3%Sector median +7.2%

Profit growth 3y–Sector median -13.6%

PEG–

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 9 companies in Healthcare Research, Analytics & Technology (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹3 cr vs borrowings ₹4 cr (FY26): borrowings are higher by ₹1 cr.
Operating profit covered interest 38.7x in the last 12 months.
Other income was 1% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹59.20 on 2026-10-26: -35.7% from the 52-week high, +31.5% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹88.80 · low ₹21.91

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	21	22	36	48	25	37
EBITDA	0	0	1	1	1	1
OPM %	1.1%	0.8%	1.9%	2.7%	5.1%	3.5%
Other income	0	0	0	0	0	0
Net profit	0	0	1	1	1	1
EPS (₹)	0.18	0.09	0.37	0.58	0.43	0.49
Revenue YoY					+20.8%	+65.1%
Profit YoY					+405.6%	+972.7%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY20	FY21	FY23	FY25	FY26	TTM
Revenue	1	1	1	31	132	147
EBITDA	-0	-4	-1	0	3	5
Net profit	0	-3	-0	0	3	4
EPS (₹)	0.12	-4.04	-0.07	0.08	1.21	1.87
Revenue growth		-3.9%	+42.4%	+2,078.7%	+330.7%	–
Profit growth		-3,370.0%	–	–	+3,100.0%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+411.3%	–	–
Net profit	–	–	–
EPS	–	–	–
Share price	–	– (2y)	+32.4%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	18	46
Borrowings	0	4
Cash & equivalents	1	3
Total assets	27	92
Fixed assets	0	2
Capital work in progress	0	–
Investments	0	0
Receivables	18	59
Inventory	1	14
Payables	9	40

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-14	-22
Cash from investing	3	-2
Cash from financing	11	26
Capex	0	3
Free cash flow	-14	-26

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	0.5%	5.5%
ROCE %	0.7%	6.7%
Debtor days	216	163
Inventory days	10	42
Payable days	115	116
Cash conversion cycle (days)	111	89
Working capital days	205	130

Peers in Healthcare Research, Analytics & Technology

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SYNGENE	₹14,527 cr	65.4x	3.0x	4.6%	7.0%	19.8%	+5.4%	0.35%
INDGN	₹14,472 cr	36.0x	4.6x	13.9%	17.4%	16.2%	–	0.33%
SUVEN	₹6,917 cr	–	11.7x	-100.5%	-59.5%	-4,155.5%	-19.3%	–
VIMTALABS	₹2,185 cr	27.4x	4.8x	19.1%	23.5%	34.3%	+8.9%	0.20%
BI	₹189 cr	4.3x	1.0x	2.3%	7.0%	8.4%	+274.4%	–
TAKE	₹154 cr	12.1x	5.0x	49.8%	20.1%	-2.0%	-34.1%	–
NOVELIX	₹141 cr	31.7x	3.0x	11.3%	8.8%	3.1%	+411.3%	–
JSTL	₹102 cr	28.5x	1.4x	6.1%	9.8%	20.5%	+19.4%	0.97%
ADESHWAR	₹23 cr	18.0x	0.9x	5.5%	10.2%	4.9%	-12.0%	–

All 9 companies in Healthcare Research, Analytics & Technology →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Healthcare Research, Analytics & Technology
Sub-industry	Healthcare Research, Analytics & Technology
Symbol	NOVELIX
BSE code	536565
ISIN	INE314I01036
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.